February 25, 2017 3:32 AM ET

Biotechnology

Company Overview of ARCA biopharma, Inc.

Company Overview

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nematode Anticoagulation Protein c2, a therapy for the disease syndrome caused by infection from hemorrhagic fever viruses and other pathogens. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3...

11080 CirclePoint Road

Suite 140

Westminster, CO 80020

United States

18 Employees

Phone:

720-940-2200

Fax:

720-208-9261

Key Executives for ARCA biopharma, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 71
Total Annual Compensation: $296.7K
Chief Operating Officer
Age: 57
Total Annual Compensation: $294.2K
Senior Vice President, General Counsel and Secretary
Age: 57
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2015.

ARCA biopharma, Inc. Key Developments

Anders Hove Joins ARCA Biopharma Board of Directors

ARCA biopharma, Inc. announced that Anders Hove, M.D., has joined its board of directors. Dr. Hove has more than 20 years of experience investing in and helping build biopharmaceutical companies. He has served on the boards of directors of numerous private and public companies, currently serving on the boards of two private biopharmaceutical companies.

ARCA biopharma, Inc. Announces Patient Randomized into the Genetic-AF Phase 2B/3 Clinical Trial

ARCA biopharma, Inc. announced that the 150th patient has been randomized into GENETIC-AF, a seamless Phase 2B/3 clinical trial evaluating GencaroTM (bucindolol hydrochloride) as a potential treatment for atrial fibrillation (AF). GENETIC-AF is a seamless Phase 2B/3 adaptive design superiority trial evaluating the effectiveness of Gencaro for the prevention of recurrent atrial fibrillation or flutter (AF/AFL) in heart failure patients with reduced left ventricular ejection fraction (HFrEF). The DSMB will perform a pre-specified interim analysis of unblinded efficacy data when at least 150 patients have evaluable data. A randomized patient has evaluable data either when they experience their first composite endpoint event, AF/AFL or all-cause mortality, or after completion of the 24-week primary endpoint follow-up period. The analysis will be conducted for detection of evidence of safety and superior efficacy of Gencaro versus the active comparator, metoprolol succinate (TOPROL-XL).

ARCA biopharma Mulls Acquisitions

ARCA biopharma, Inc. (NasdaqCM:ABIO) is seeking acquisitions. ARCA announced an equity offering with an offering price of up to $7.3 million. It may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ARCA biopharma, Inc., please visit www.arcabiopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.